We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
-24.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$850M
Cap. Flow
+$1.05B
Cap. Flow %
101.26%
Top 10 Hldgs %
100%
Holding
7
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CHPT icon
ChargePoint
CHPT
+$846M
2
ONTF
ON24
ONTF
+$212M

Top Sells

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$4.75M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 64.34%
2 Healthcare 17.13%
3 Technology 16.97%
4 Communication Services 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHPT icon
1
ChargePoint
CHPT
$133M
$669M 64.34%
+1,252,808
New +$846M
ONTF
2
DELISTED
ON24
ONTF
$176M 16.97%
+3,637,894
New +$212M
NGM
3
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$109M 10.53%
3,766,666
– –
TVRD
4
Tvardi Therapeutics
TVRD
$23.5M
$55.3M 5.32%
70,807
-6,945
-9% -$4.75M
LVO icon
5
LiveOne
LVO
$66M
$16.2M 1.55%
372,414
– –
MRSN
6
DELISTED
Mersana Therapeutics
MRSN
$12.9M 1.24%
31,858
– –
SENS icon
7
Senseonics Holdings Inc
SENS
$254M
$421K 0.04%
7,980
– –

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Rho Capital Partners held 7 positions worth $1.04B, up 447% from $190M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners deployed $1.05B of net new capital in Q1 2021, opening 2 new positions. Its largest new stake was ChargePoint: 1,252,808 shares worth $669M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 64% of assets, followed by Healthcare and Technology.

On the sell side, the largest reduction was Tvardi Therapeutics, an estimated $4.75M trimmed.

  • Rho Capital Partners's largest Q1 2021 buy was ChargePoint: 1,252,808 shares worth $669M.
  • Rho Capital Partners's biggest Q1 2021 reduction was Tvardi Therapeutics, cutting an estimated $4.75M.
  • Rho Capital Partners's ten largest holdings make up 100% of its $1.04B portfolio in Q1 2021.
  • Rho Capital Partners opened 2 new positions and closed 0 in Q1 2021.
  • Rho Capital Partners's portfolio value rose 447% quarter-over-quarter to $1.04B.

Based on Rho Capital Partners's 13F filing for Q1 2021, filed 13 May 2021.